However, there are difficulties and inconsistencies in the clinical protocols to determine the rate of PDL1+ cancer cells in biopsy material as there is no fully standardized detection antibody, definition of cutoffs for the evaluation of the stainings, tissue preparation, and processing protocols available yet. This evidence concerns the gene CD274 and cancer.